Homepage
Author:
Servier Pharmaceuticals LLC
Posted Date:
May 22, 2026
Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio
Servier Pharmaceuticals LLC
May 22, 2026
Emiltatug Ledadotin (Emi-Le) Granted Breakthrough Therapy Designation by the U.S. FDA for Adenoid Cystic Carcinoma (ACC)
Servier Pharmaceuticals LLC
May 12, 2026
Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG)
Servier Pharmaceuticals LLC
May 11, 2026
